Fundraising Fox

/Companies

Lisata Therapeutics

NASDAQ: LSTA

Basking Ridge, US · Founded 2006 · Delaware corporation · 35 employees on LinkedIn

Find your way into Lisata Therapeutics

713 people in our graph can introduce you to the Lisata Therapeutics team.

Sign up to see every warm intro you have to Lisata Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Lisata Therapeutics team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Lisata Therapeutics is a clinical-stage biopharmaceutical company developing certepetide, an investigational peptide designed to enhance the delivery and efficacy of anti-cancer drugs to solid tumors by activating a tumor-specific transport mechanism, while also modifying the tumor microenvironment to improve response to immunotherapy. The company is pursuing clinical development of certepetide in combination with chemotherapy and immunotherapy across multiple solid tumor types including pancreatic cancer, cholangiocarcinoma, and glioblastoma.

Founders & leadership

DJ

David J. Mazzo

David J. Mazzo ExecutiveDavid Mazzo holds a Ph.D. in analytical chemistry from the University of Massachusetts, Amherst, and has served as CEO of multiple biopharmaceutical companies including Regado Biosciences, Æterna Zentaris, and Chugai Pharma USA, as well as senior roles at Schering-Plough Research Institute, Hoechst Marion Roussel, and Rhone-Poulenc Rorer; he is currently President and CEO of Lisata Therapeutics.

JT

Joseph TalamoExecutive

RA

Robert A. Preti

Robert A. PretiExecutiveExecutive Officer, Director at Caladrius Biosciences

AL

Andrew L. Pecora

Andrew L. Pecora ExecutiveDirector at Caladrius Biosciences

SW

Stephen W. Potter

Stephen W. PotterExecutiveExecutive Officer at Caladrius Biosciences

RD

Robert Dickey IVExecutive

CV

Catherine Vaczy

Catherine VaczyExecutiveExecutive Officer at Caladrius Biosciences

DL

Douglas Losordo

Douglas Losordo ExecutiveExecutive Officer at Cadrenal Therapeutics

KK

Kristen K. Buck

Kristen K. Buck Executive Vice President of Research & Development and Chief Medical OfficerExecutive Vice President of Research & Development and Chief Medical Officer at Caladrius Biosciences

JN

James Nisco

James Nisco Senior Vice President Finance and Treasury and Chief Accounting OfficerSenior Vice President Finance and Treasury and Chief Accounting Officer at Caladrius Biosciences

TI

TARIQ IMAMNamed on SEC filingExecutive Officer at Caladrius Biosciences

GB

GREGORY BROWNNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$435.1M disclosed across 8 rounds · 2014–2026

▶$351.9MraisedOct 2026 · 20 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

DAVID MAZZOExecutive Officer, Director
JAMES NISCOExecutive Officer
TARIQ IMAMExecutive Officer
GREGORY BROWNDirector
HEIDI HENSONDirector
CYNTHIA FLOWERSDirector
STEVEN KLOSKDirector
MOHAMMAD AZABDirector
TED LOVEDirector

Offering amount: $351.9M
Amount sold: $351.9M
Sales commissions: $2.6M
Placement agents: H.C.WAINWRIGHT & CO., LLC, LEERINK PARTNERS LLC, LIFESCI CAPITAL
First sale: Sep 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25MraisedFeb 2021 · 23 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Steven M. KloskDirector
Gregory B. BrownDirector
Steven S. MyersDirector
Cynthia SchwalmDirector
Peter G. TraberDirector
Anne WhitakerDirector
David J. MazzoExecutive Officer, Director
Michael DavidsonDirector

Offering amount: $25M
Amount sold: $25M
Sales commissions: $1.8M
Placement agents: H.C. Wainwright & Co., LLC3
First sale: Jan 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2MraisedJul 2020 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joseph TalamoExecutive Officer
Cynthia SchwalmDirector
Peter G. TraberDirector
Steven S. MyersDirector
Steven M. KloskDirector
David J. MazzoExecutive Officer, Director
Douglas LosordoExecutive Officer
Gregory B. BrownDirector

Offering amount: $2M
Amount sold: $2M
First sale: Jul 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.2MraisedJun 2020 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Douglas LosordoExecutive Officer
Peter G. TraberDirector
Gregory B. BrownDirector
Joseph TalamoExecutive Officer
David J. MazzoExecutive Officer
Steven S. MyersDirector
Cynthia SchwalmDirector
Steven M. KloskDirector

Offering amount: $2.2M
Amount sold: $2.2M
Sales commissions: $301K
Placement agents: H.C. Wainwright & Co., LLC
First sale: May 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$2.4MraisedMay 2020 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Peter G. TraberDirector
Steven M. KloskDirector
Gregory B. BrownDirector
Douglas LosordoExecutive Officer
Cynthia SchwalmDirector
David J. MazzoExecutive Officer
Joseph TalamoExecutive Officer
Steven S. MyersDirector

Offering amount: $2.4M
Amount sold: $2.4M
Sales commissions: $350K
Placement agents: H.C. Wainwright & Co., LLC
First sale: Apr 2020
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$12.6MraisedSep 2016 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David MazzoExecutive Officer, Director
Peter TraberDirector
Douglas LosordoExecutive Officer
Joseph TalamoExecutive Officer
Andrew L. PecoraDirector
Steven M. KloskDirector
Richard BermanDirector
Steven S. MyersDirector
Eric WeiDirector
Robert A. PretiExecutive Officer, Director

Offering amount: $21M
Amount sold: $12.6M
First sale: Sep 2016
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedMar 2016 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

David J. MazzoExecutive Officer, Director
Steven S. MyersDirector
Joseph TalamoExecutive Officer
Peter TraberDirector
Robert A. PretiExecutive Officer, Director
Steven M. KloskDirector
Richard BermanDirector
Eric WeiDirector
Andrew L. PecoraDirector

Offering amount: $1M
Amount sold: $1M
First sale: Mar 2016
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$38MraisedMay 2014 · 142 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Robert PretiExecutive Officer
Stephen W. PotterExecutive Officer
Martyn D. GreenacreDirector
Robert Dickey IVExecutive Officer
Richard BermanDirector
Andrew L. PecoraExecutive Officer, Director
Catherine VaczyExecutive Officer
Joseph TalamoExecutive Officer
Douglas LosordoExecutive Officer
Drew BernsteinDirector
Steven S. MyersDirector
Eric H.C. WeiDirector
Robin L. SmithExecutive Officer, Director

Offering amount: $38M
Amount sold: $38M
Finders' fees: $1.5M
Placement agents: Piper Jaffray & Co.
First sale: May 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Lisata Therapeutics do?: Lisata Therapeutics is a clinical-stage biopharmaceutical company developing certepetide, an investigational peptide designed to enhance the delivery and efficacy of anti-cancer drugs to solid tumors by activating a tumor-specific transport mechanism, while also modifying the tumor microenvironment to improve response to immunotherapy. The company is pursuing clinical development of certepetide in combination with chemotherapy and immunotherapy across multiple solid tumor types including pancreatic cancer, cholangiocarcinoma, and glioblastoma.
How much funding has Lisata Therapeutics raised?: Lisata Therapeutics has disclosed $435.1M raised across 8 rounds.
Where is Lisata Therapeutics headquartered?: Lisata Therapeutics is headquartered in Basking Ridge, US.